Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Paclitaxel-based regimens as first-line treatment in advanced gastric cancer.

Guo Z, Wang X, Lin R, Chen L, Fan N, Chen Y, Lin J, Yu J.

J Chemother. 2015 Feb;27(2):94-8. doi: 10.1179/1973947814Y.0000000169. Epub 2014 Feb 18.

PMID:
24548091
2.

Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.

Springfeld C, Wiecha C, Kunzmann R, Heger U, Weichert W, Langer R, Stange A, Blank S, Sisic L, Schmidt T, Lordick F, Jäger D, Grenacher L, Bruckner T, Büchler MW, Ott K.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S905-14. doi: 10.1245/s10434-015-4617-x. Epub 2015 May 22.

PMID:
26001861
3.

Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.

Shitara K, Muro K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, Nishina T, Yamaguchi K, Segawa Y, Omuro Y, Tamura T, Doi T, Yukisawa S, Yasui H, Nagashima F, Gotoh M, Esaki T, Emig M, Chandrawansa K, Liepa AM, Wilke H, Ichimiya Y, Ohtsu A.

Gastric Cancer. 2016 Jul;19(3):927-38. doi: 10.1007/s10120-015-0559-z. Epub 2015 Oct 28.

PMID:
26510663
4.

Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer.

Muro K, Oh SC, Shimada Y, Lee KW, Yen CJ, Chao Y, Cho JY, Cheng R, Carlesi R, Chandrawansa K, Orlando M, Ohtsu A.

J Gastroenterol Hepatol. 2016 Mar;31(3):581-9. doi: 10.1111/jgh.13153.

PMID:
26317322
5.

Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia.

Hecht JR, Blanke CD, Benson AB 3rd, Lenz HJ.

Oncology (Williston Park). 2003 Sep;17(9 Suppl 8):13-5.

7.

[Second-line treatment for metastatic or locally advanced gastric cancer].

Li KC, Cheng SY, Du J, Li J.

Zhonghua Zhong Liu Za Zhi. 2016 Oct 23;38(10):721-724. doi: 10.3760/cma.j.issn.0253-3766.2016.10.001. Chinese.

PMID:
27784452
8.

The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma.

Garrido M.

Expert Rev Anticancer Ther. 2016 Oct;16(10):1005-10. doi: 10.1080/14737140.2016.1231576. Epub 2016 Sep 14. Review.

PMID:
27582051
9.

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma.

Al-Batran SE, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov ON, Kim TY, Cunningham D, Rougier P, Muro K, Liepa AM, Chandrawansa K, Emig M, Ohtsu A, Wilke H.

Ann Oncol. 2016 Apr;27(4):673-9. doi: 10.1093/annonc/mdv625. Epub 2016 Jan 7.

10.

Efficacy and Safety of Weekly Paclitaxel Therapy for Advanced Gastric Cancer Patients with Disseminated Intravascular Coagulation.

Kawai S, Sakamoto Y, Takahashi Y, Ichikawa S, Gamoh M.

J Gastrointest Cancer. 2015 Dec;46(4):438-41. doi: 10.1007/s12029-015-9744-x. No abstract available.

PMID:
26142346
11.

TP53 Codon 72 Polymorphism Predicts Efficacy of Paclitaxel Plus Capecitabine Chemotherapy in Advanced Gastric Cancer Patients.

Zha Y, Gan P, Liu Q, Yao Q.

Arch Med Res. 2016 Jan;47(1):13-8. doi: 10.1016/j.arcmed.2015.12.001. Epub 2015 Dec 13.

PMID:
26696550
12.

Ramucirumab: A Review in Advanced Gastric Cancer.

Greig SL, Keating GM.

BioDrugs. 2015 Oct;29(5):341-51. doi: 10.1007/s40259-015-0138-1. Review.

PMID:
26341713
13.

Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis.

Mohammad NH, ter Veer E, Ngai L, Mali R, van Oijen MG, van Laarhoven HW.

Cancer Metastasis Rev. 2015 Sep;34(3):429-41. doi: 10.1007/s10555-015-9576-y. Review.

14.

Ramucirumab: first global approval.

Poole RM, Vaidya A.

Drugs. 2014 Jun;74(9):1047-58. doi: 10.1007/s40265-014-0244-2. Review.

PMID:
24916147
15.

[A case showing a complete response by weekly paclitaxel associated with severe empyema and mediastinal abscess caused by reduction of a recurrent lung metastatic tumor originating from adenocarcinoma of the esophagogastric junction after primary operation].

Kimura A, Hiramatsu K, Sakuragawa T, Ito T, Otsuji H, Tsuchiya T, Hara T, Maeda T, Tanaka H, Machiki Y, Hosoya J, Kojima T, Kato K.

Gan To Kagaku Ryoho. 2010 Feb;37(2):303-5. Japanese.

PMID:
20154490
16.

Gastrointestinal cancer: FOLFIRI-improving toxicity in first-line treatment of advanced gastric cancer.

Errico A.

Nat Rev Clin Oncol. 2014 Dec;11(12):684. doi: 10.1038/nrclinonc.2014.184. Epub 2014 Oct 21. No abstract available.

PMID:
25331178
17.

Time-to-Treatment Failure As the Primary End Point of a First-Line Advanced Gastric Cancer Randomized Trial: How Confused Would You Want Us to Be?

Elimova E, Ajani JA.

J Clin Oncol. 2015 Jul 20;33(21):2410. doi: 10.1200/JCO.2014.59.8847. Epub 2015 Jun 15. No abstract available.

PMID:
26077236
18.

Acute hypertension during ramucirumab infusion in two patients with advanced oesophagogastric cancer.

van der Woude SO, van Laarhoven HW.

BMJ Case Rep. 2016 Aug 18;2016. pii: bcr2016215801. doi: 10.1136/bcr-2016-215801.

PMID:
27539134
19.

Gastrointestinal cancer. Over the RAINBOW--renaissance in antiangiogenesis.

Lordick F.

Nat Rev Clin Oncol. 2015 Jan;12(1):7-8. doi: 10.1038/nrclinonc.2014.195. Epub 2014 Nov 18.

PMID:
25403941
20.

Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials.

Galdy S, Cella CA, Spada F, Murgioni S, Frezza AM, Ravenda SP, Zampino MG, Fazio N.

Crit Rev Oncol Hematol. 2016 Mar;99:1-12. doi: 10.1016/j.critrevonc.2015.09.004. Epub 2015 Nov 30. Review.

PMID:
26697987

Supplemental Content

Support Center